ImmuCell (NASDAQ:ICCC) Share Price Passes Above 200-Day Moving Average – What’s Next?

ImmuCell Co. (NASDAQ:ICCC)’s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.40 and traded as high as $4.97. ImmuCell shares last traded at $4.97, with a volume of 2,110 shares changing hands.

ImmuCell Stock Up 2.6 %

The company has a 50-day moving average price of $5.17 and a 200 day moving average price of $4.41. The firm has a market capitalization of $43.98 million, a PE ratio of -9.87 and a beta of 0.62. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.11 and a quick ratio of 1.44.

ImmuCell (NASDAQ:ICCC) last announced its quarterly earnings results on Tuesday, February 25th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter. The company had revenue of $7.75 million for the quarter. ImmuCell had a negative net margin of 15.99% and a negative return on equity of 15.32%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Mesirow Financial Investment Management Inc. grew its stake in shares of ImmuCell by 100.0% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company’s stock worth $125,000 after buying an additional 12,178 shares in the last quarter. Citadel Advisors LLC purchased a new position in ImmuCell in the fourth quarter worth about $149,000. Northern Trust Corp grew its position in ImmuCell by 51.0% in the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company’s stock worth $229,000 after acquiring an additional 14,982 shares in the last quarter. Geode Capital Management LLC increased its stake in ImmuCell by 13.9% during the fourth quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company’s stock worth $332,000 after acquiring an additional 7,878 shares during the last quarter. Finally, Dauntless Investment Group LLC purchased a new stake in ImmuCell during the fourth quarter valued at approximately $676,000. 13.47% of the stock is owned by hedge funds and other institutional investors.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.